Drug Profile
SB 239063
Alternative Names: 239063Latest Information Update: 09 Feb 2006
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Imidazoles; Neuroprotectants; Pyrimidines
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Stroke
Most Recent Events
- 09 Feb 2006 No development reported - Preclinical for Asthma in USA (PO)
- 22 Jun 2004 Preclinical trials in Asthma in USA (PO)
- 22 Jun 2004 Data presented at the 100th International Conference of the American Thoracic Society (ATS-2004) have been added to the Obstructive Airways Disease pharmacodynamics section